SanegeneBio signs USD1.5B licensing agreement with Genentech for its RNAi therapy platform

USA—SanegeneBio has struck a major USD1.5 billion global licensing agreement with Genentech, a member of the Roche Group, marking a significant advancement in the field of ribonucleic acid interference therapeutics.

The deal centers on one of SanegeneBio’s innovative RNAi programs and grants Genentech exclusive worldwide rights to develop and bring the treatment to market.

Partnership structure and financial terms

The agreement provides SanegeneBio with an immediate upfront payment of USD 200 million.

Beyond this initial sum, the biotechnology company stands to receive development and commercialization milestone payments that could reach up to USD1.5 billion in total value.

The financial package also includes tiered royalty payments based on future product sales, creating a long-term revenue stream tied to the therapy’s commercial success.

Under the terms of the collaboration, SanegeneBio will handle the early-stage development activities for the RNAi program.

Genentech will then take over all subsequent clinical development phases and assume responsibility for commercializing the product across global markets.

This division of responsibilities allows SanegeneBio to leverage its platform expertise while benefiting from Genentech’s extensive capabilities in late-stage drug development and worldwide distribution.

innovative RNAi technology platform

The partnership focuses on SanegeneBio’s proprietary RNAi platform, which incorporates novel chemistries and advanced delivery technologies.

These innovations enable the creation of small interfering ribonucleic acid medicines designed to target diseases across multiple therapeutic areas.

The platform represents a differentiated approach to RNAi therapeutics, offering potential advantages in how these treatments reach their intended targets within the body.

Weimin Wang, who serves as both chief executive officer and founder of SanegeneBio, emphasized the significance of this partnership.

He described the agreement with Genentech as another crucial milestone for the company’s innovative and differentiated RNAi chemistry and delivery platforms.

Wang expressed enthusiasm about collaborating with a global scientific leader, stating that the partnership will help deliver effective, life-changing therapies to patients worldwide.

Company background and research focus

SanegeneBio operates as a venture-backed biotechnology company dedicated to advancing RNAi-based therapeutic solutions.

The company maintains research and development operations across three strategic locations: Shanghai and Suzhou in China, and Boston in the United States.

This international footprint positions the company to tap into diverse scientific talent and research ecosystems.

The company’s development pipeline encompasses experimental medicines addressing several critical health areas, including cardiometabolic indications, obesity, and autoimmune nephropathies.

SanegeneBio has already launched clinical trials for four experimental medicines targeting these conditions, utilizing its proprietary LEAD tissue-selective RNAi delivery technology.

This delivery system represents a key differentiator, potentially allowing treatments to reach specific tissues more effectively while minimizing off-target effects.

Expanding strategic partnerships

The Genentech agreement represents the second major partnership SanegeneBio has announced in recent months.

In November 2025, the company formed a worldwide research and licensing partnership with Eli Lilly and Company.

That collaboration focuses on developing RNAi candidates specifically for metabolic diseases, demonstrating pharmaceutical industry confidence in SanegeneBio’s technology platform and its potential applications across different disease areas.

These back-to-back partnerships with two pharmaceutical giants underscore the growing interest in RNAi therapeutics and validate SanegeneBio’s approach to this emerging treatment modality.

The agreements provide the company with substantial financial resources to advance its research while gaining access to the development and commercialization expertise of established industry leaders.